GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » PS Ratio
中文

Fortress Biotech (Fortress Biotech) PS Ratio : 0.17 (As of Apr. 25, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Fortress Biotech's share price is $1.79. Fortress Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.68. Hence, Fortress Biotech's PS Ratio for today is 0.17.

The historical rank and industry rank for Fortress Biotech's PS Ratio or its related term are showing as below:

FBIO' s PS Ratio Range Over the Past 10 Years
Min: 0.11   Med: 3.28   Max: 335.57
Current: 0.17

During the past 13 years, Fortress Biotech's highest PS Ratio was 335.57. The lowest was 0.11. And the median was 3.28.

FBIO's PS Ratio is ranked better than
98.59% of 991 companies
in the Biotechnology industry
Industry Median: 8.98 vs FBIO: 0.17

Fortress Biotech's Revenue per Sharefor the three months ended in Dec. 2023 was $1.85. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.68.

Warning Sign:

Fortress Biotech Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Fortress Biotech was -18.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 3.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.60% per year.

During the past 13 years, Fortress Biotech's highest 3-Year average Revenue per Share Growth Rate was 203.80% per year. The lowest was 3.10% per year. And the median was 13.00% per year.

Back to Basics: PS Ratio


Fortress Biotech PS Ratio Historical Data

The historical data trend for Fortress Biotech's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech PS Ratio Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 5.01 2.97 0.77 0.29

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 1.17 0.85 0.38 0.29

Competitive Comparison of Fortress Biotech's PS Ratio

For the Biotechnology subindustry, Fortress Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's PS Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's PS Ratio falls into.



Fortress Biotech PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Fortress Biotech's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.79/10.678
=0.17

Fortress Biotech's Share Price of today is $1.79.
Fortress Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.68.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Fortress Biotech  (NAS:FBIO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Fortress Biotech PS Ratio Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

By Value_Insider Value_Insider 12-19-2022

Fortress Biotech Appoints David Jin as Chief Financial Officer

By PurpleRose PurpleRose 07-22-2022